Needham & Company Reiterates Buy Rating on Vaxcyte (PCVX)

April 4, 2022 3:53 PM EDT Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $52.00 price target on Vaxcyte (NASDAQ: PCVX), as the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login